Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Downgraded to “Hold” Rating by Zacks Research

by · The Cerbat Gem

Zacks Research downgraded shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA – Free Report) from a strong-buy rating to a hold rating in a research note published on Thursday morning,Zacks.com reports.

Several other brokerages have also commented on KNSA. Jefferies Financial Group upped their price target on Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the stock a “buy” rating in a research note on Tuesday, April 28th. The Goldman Sachs Group increased their target price on shares of Kiniksa Pharmaceuticals International from $75.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday. Wells Fargo & Company lifted their price target on shares of Kiniksa Pharmaceuticals International from $57.00 to $74.00 and gave the company an “overweight” rating in a research report on Monday, July 13th. Wedbush raised their target price on shares of Kiniksa Pharmaceuticals International from $72.00 to $99.00 and gave the company an “outperform” rating in a research note on Wednesday. Finally, JPMorgan Chase & Co. upped their price target on shares of Kiniksa Pharmaceuticals International from $72.00 to $107.00 and gave the stock an “overweight” rating in a research report on Wednesday. Nine research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $87.38.

Get Our Latest Stock Report on KNSA

Kiniksa Pharmaceuticals International Stock Performance

Shares of KNSA stock opened at $74.34 on Thursday. Kiniksa Pharmaceuticals International has a one year low of $29.90 and a one year high of $82.94. The company has a 50 day moving average price of $59.04 and a 200 day moving average price of $51.13. The firm has a market capitalization of $5.72 billion, a price-to-earnings ratio of 76.64 and a beta of 0.07.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA – Get Free Report) last announced its quarterly earnings results on Tuesday, July 28th. The company reported $0.30 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.30. The company had revenue of $243.60 million for the quarter, compared to analyst estimates of $226.49 million. Kiniksa Pharmaceuticals International had a net margin of 9.59% and a return on equity of 13.65%. As a group, equities analysts forecast that Kiniksa Pharmaceuticals International will post 1.38 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director G Bradley Cole sold 3,673 shares of Kiniksa Pharmaceuticals International stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $81.43, for a total transaction of $299,092.39. Following the sale, the director owned 11,672 shares of the company’s stock, valued at $950,450.96. The trade was a 23.94% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 51.98% of the company’s stock.

Institutional Trading of Kiniksa Pharmaceuticals International

Hedge funds and other institutional investors have recently modified their holdings of the business. Qube Research & Technologies Ltd boosted its holdings in Kiniksa Pharmaceuticals International by 277.8% in the second quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock valued at $24,581,000 after purchasing an additional 653,236 shares during the last quarter. Rubric Capital Management LP raised its position in shares of Kiniksa Pharmaceuticals International by 15.6% in the 2nd quarter. Rubric Capital Management LP now owns 3,909,806 shares of the company’s stock valued at $108,184,000 after purchasing an additional 526,567 shares in the last quarter. Bank of America Corp DE raised its position in shares of Kiniksa Pharmaceuticals International by 220.9% in the 1st quarter. Bank of America Corp DE now owns 735,940 shares of the company’s stock valued at $35,436,000 after purchasing an additional 506,576 shares in the last quarter. Cubist Systematic Strategies LLC boosted its stake in shares of Kiniksa Pharmaceuticals International by 213.2% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 657,475 shares of the company’s stock valued at $18,192,000 after buying an additional 447,536 shares during the last quarter. Finally, Spruce Street Capital LP purchased a new position in shares of Kiniksa Pharmaceuticals International during the 4th quarter valued at approximately $17,943,000. 53.95% of the stock is owned by hedge funds and other institutional investors.

About Kiniksa Pharmaceuticals International

(Get Free Report)

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.

Featured Articles